Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
7.88
-0.30 (-3.67%)
At close: Apr 28, 2026, 4:00 PM EDT
7.92
+0.04 (0.51%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Xilio Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 43.77 | 6.34 | - | - | - | |
| Revenue Growth (YoY) | 589.88% | - | - | - | - | |
| Gross Profit | 43.77 | 6.34 | - | - | - | |
| Selling, General & Admin | 29.71 | 24.78 | 27 | 29.95 | 23.86 | |
| Research & Development | 56.04 | 41.21 | 52.14 | 59.2 | 51.19 | |
| Operating Expenses | 85.75 | 65.99 | 79.13 | 89.15 | 75.04 | |
| Operating Income | -41.98 | -59.65 | -79.13 | -89.15 | -75.04 | |
| Interest Expense | - | - | -0.7 | -0.8 | -0.6 | |
| Other Non Operating Income (Expenses) | 6.95 | 2.34 | 3.43 | 1.73 | -0.16 | |
| EBT Excluding Unusual Items | -35.04 | -57.3 | -76.4 | -88.22 | -75.8 | |
| Merger & Restructuring Charges | - | -0.94 | - | - | - | |
| Pretax Income | -35.04 | -58.24 | -76.4 | -88.22 | -75.8 | |
| Net Income | -35.04 | -58.24 | -76.4 | -88.22 | -75.8 | |
| Net Income to Common | -35.04 | -58.24 | -76.4 | -88.22 | -75.8 | |
| Shares Outstanding (Basic) | 5 | 4 | 2 | 2 | 0 | |
| Shares Outstanding (Diluted) | 5 | 4 | 2 | 2 | 0 | |
| Shares Change (YoY) | 18.53% | 94.61% | 0.38% | 388.59% | 970.35% | |
| EPS (Basic) | -7.73 | -15.24 | -38.90 | -45.09 | -189.29 | |
| EPS (Diluted) | -7.73 | -15.24 | -38.90 | -45.09 | -189.29 | |
| Free Cash Flow | -5.51 | -18.41 | -69.11 | -77.59 | -81.85 | |
| Free Cash Flow Per Share | -1.22 | -4.82 | -35.19 | -39.66 | -204.40 | |
| Gross Margin | 100.00% | 100.00% | - | - | - | |
| Operating Margin | -95.92% | -940.18% | - | - | - | |
| Profit Margin | -80.05% | -918.05% | - | - | - | |
| Free Cash Flow Margin | -12.59% | -290.26% | - | - | - | |
| EBITDA | -40.44 | -58 | -77.23 | -87.3 | -73.55 | |
| EBITDA Margin | -92.40% | - | - | - | - | |
| D&A For EBITDA | 1.54 | 1.64 | 1.9 | 1.85 | 1.5 | |
| EBIT | -41.98 | -59.65 | -79.13 | -89.15 | -75.04 | |
| EBIT Margin | -95.92% | - | - | - | - | |
| Revenue as Reported | 43.77 | 6.34 | - | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.